{"title":"日本睾丸癌幸存者的合并症：一项多机构横断面研究。","authors":"Juntaro Koyama, Shinichi Yamashita, Kenichi Kakimoto, Motohide Uemura, Takeshi Kishida, Koji Kawai, Terukazu Nakamura, Takayuki Goto, Takahiro Osawa, Kazuo Nishimura, Norio Nonomura, Hiroyuki Nishiyama, Takumi Shiraishi, Osamu Ukimura, Osamu Ogawa, Nobuo Shinohara, Yoshimi Suzukamo, Akihiro Ito, Yoichi Arai","doi":"10.1111/iju.15622","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To evaluate comorbidities in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study enrolled TC survivors who visited any of the eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants answered questionnaires about their comorbidities. We analyzed the impact of treatment on comorbidities rate in TC survivors.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 509 TC survivors responded to the comorbidity questionnaires. Median age at the time of response was 43 years (IQR 35–51 years) and median follow-up period after treatment was 5.1 years (IQR 2.1–9.2 years). TC survivors were divided according to the number of cycles of chemotherapy into the following groups: None (<i>n</i> = 153); 1–2 cycles (<i>n</i> = 34); 3–4 cycles (<i>n</i> = 234); or ≥5 cycles (<i>n</i> = 88). The prevalence of kidney disease increased significantly with increasing number of cycles of chemotherapy (<i>p</i> < 0.05). The relative risk of cardiovascular disease in the groups with three or more cycles was 2.6 compared to the group without chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The present study showed that the prevalence of kidney disease in TC survivors was increased with increasing number of cycles of chemotherapy.</p>\n </section>\n </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"198-202"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comorbidities in Japanese testicular cancer survivors: A multi-institutional, cross-sectional study\",\"authors\":\"Juntaro Koyama, Shinichi Yamashita, Kenichi Kakimoto, Motohide Uemura, Takeshi Kishida, Koji Kawai, Terukazu Nakamura, Takayuki Goto, Takahiro Osawa, Kazuo Nishimura, Norio Nonomura, Hiroyuki Nishiyama, Takumi Shiraishi, Osamu Ukimura, Osamu Ogawa, Nobuo Shinohara, Yoshimi Suzukamo, Akihiro Ito, Yoichi Arai\",\"doi\":\"10.1111/iju.15622\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To evaluate comorbidities in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This study enrolled TC survivors who visited any of the eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants answered questionnaires about their comorbidities. We analyzed the impact of treatment on comorbidities rate in TC survivors.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 509 TC survivors responded to the comorbidity questionnaires. Median age at the time of response was 43 years (IQR 35–51 years) and median follow-up period after treatment was 5.1 years (IQR 2.1–9.2 years). TC survivors were divided according to the number of cycles of chemotherapy into the following groups: None (<i>n</i> = 153); 1–2 cycles (<i>n</i> = 34); 3–4 cycles (<i>n</i> = 234); or ≥5 cycles (<i>n</i> = 88). The prevalence of kidney disease increased significantly with increasing number of cycles of chemotherapy (<i>p</i> < 0.05). The relative risk of cardiovascular disease in the groups with three or more cycles was 2.6 compared to the group without chemotherapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The present study showed that the prevalence of kidney disease in TC survivors was increased with increasing number of cycles of chemotherapy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":14323,\"journal\":{\"name\":\"International Journal of Urology\",\"volume\":\"32 2\",\"pages\":\"198-202\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/iju.15622\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/iju.15622","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Comorbidities in Japanese testicular cancer survivors: A multi-institutional, cross-sectional study
Objective
To evaluate comorbidities in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study.
Methods
This study enrolled TC survivors who visited any of the eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants answered questionnaires about their comorbidities. We analyzed the impact of treatment on comorbidities rate in TC survivors.
Results
A total of 509 TC survivors responded to the comorbidity questionnaires. Median age at the time of response was 43 years (IQR 35–51 years) and median follow-up period after treatment was 5.1 years (IQR 2.1–9.2 years). TC survivors were divided according to the number of cycles of chemotherapy into the following groups: None (n = 153); 1–2 cycles (n = 34); 3–4 cycles (n = 234); or ≥5 cycles (n = 88). The prevalence of kidney disease increased significantly with increasing number of cycles of chemotherapy (p < 0.05). The relative risk of cardiovascular disease in the groups with three or more cycles was 2.6 compared to the group without chemotherapy.
Conclusion
The present study showed that the prevalence of kidney disease in TC survivors was increased with increasing number of cycles of chemotherapy.
期刊介绍：
International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
